RecruitingPhase 1NCT06760364

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Enrollment

21 participants

Start Date

Dec 25, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Pancreatic Cancers

Summary

Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called CHT102 for people with advanced or metastatic pancreatic cancer whose cancer cells carry a protein called mesothelin (MSLN). The drug targets that protein to try to fight the cancer. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced or metastatic pancreatic cancer confirmed by biopsy - Standard treatments have not worked for you or you could not tolerate them - Your cancer tests positive for mesothelin - You have at least one measurable tumor on imaging - You are expected to live at least 3 more months - Your organs are functioning adequately **You may NOT be eligible if...** - Your cancer has not been confirmed by tissue testing - You are in poor general health (ECOG score above 1) - You have organ failure or inadequate lab values Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.